AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Food & Medicine Homology Resources Article
PDF (5.6 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Opinion | Open Access | Online First

Sulforaphane in chronic disease intervention: Clinical evidence, translational challenges, and targeted nutrition strategies

Xiao-Long Li1,†, Yong Zhu2,†, Ji-Jun Wang3,4, Dao-Ping Wang5, Ning-Xian Yang5,6( )
Shenzhen Fushan Biotech Co., Ltd., Shenzhen 518000, China
Shenzhen Key Laboratory of Steroid Drug Discovery and Development, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China
Neuromodulation Center, Shanghai Key Laboratory of Mental Disorders Translational Research, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China
Mental and Psychological Rehabilitation Research Center, Center of Yuanshen Rehabilitation Institute, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Natural Products Research Center of Guizhou Province, Guizhou Medical University, Guiyang 550014, China
The Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Provincial Engineering Research Center of Ecological Food Innovation, School of Public Health, Guizhou Medical University, Guiyang 561113, China

† Xiao-Long Li and Yong Zhu contributed equally to this work.

Show Author Information

Highlights

(1) Human clinical evidence for sulforaphane across chronic diseases is critically evaluated.

(2) Variable SFN exposure remains a major barrier to reproducible clinical translation.

(3) Three translational strategies for improving SFN delivery and conversion are compared.

(4) Future SFN research should integrate exposure, population stratification, and clinical endpoints.

Graphical Abstract

SFN derived from cruciferous plants can activate Nrf2-related defense mechanisms and shows potential in chronic disease intervention. This Perspective compares three SFN translational strategies—direct stabilization of SFN, functional-bacterial conversion of GRN, and GRN–myrosinase co-delivery—and proposes a targeted nutrition translation framework centered on reproducible human exposure.

Electronic Supplementary Material

Download File(s)
FMHR9740005_ESM.pdf (358.6 KB)

References

【1】
【1】
 
 
Crossref Google Scholar
Food & Medicine Homology Resources
DOI: 10.26599/FMHR.2026.9740005

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Li X-L, Zhu Y, Wang J-J, et al. Sulforaphane in chronic disease intervention: Clinical evidence, translational challenges, and targeted nutrition strategies. Food & Medicine Homology Resources, 2026, https://doi.org/10.26599/FMHR.2026.9740005

70

Views

29

Downloads

0

Crossref
Received: 20 August 2026
Revised: 25 August 2026
Accepted: 26 August 2026
Published: 12 October 2026
© National R & D Center for Edible Fungus Processing Technology, China 2026.

This is an open access article under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0, https://creativecommons.org/licenses/by/4.0/).